published meta-analysis   sensitivity analysis   studies

Hydrocortisone in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCAPE-COVID, 2020 0.45 [0.20; 1.02] 0.45[0.20; 1.02]CAPE-COVID, 202010%149NAnot evaluable death or ventilationdetailed resultsCAPE-COVID, 2020 0.71 [0.37; 1.35] 0.71[0.37; 1.35]CAPE-COVID, 202010%149NAnot evaluable hospital dischargedetailed resultsCAPE-COVID, 2020 1.67 [0.87; 3.19] 1.67[0.87; 3.19]CAPE-COVID, 202010%149NAnot evaluable mechanical ventilationdetailed resultsCAPE-COVID, 2020 0.95 [0.44; 2.04] 0.95[0.44; 2.04]CAPE-COVID, 202010%149NAnot evaluable superinfectiondetailed resultsCAPE-COVID, 2020 0.81 [0.49; 1.34] 0.81[0.49; 1.34]CAPE-COVID, 202010%149NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-04-25 17:56 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 737 - roots T: 290